摘要
目的探讨胃癌患者手术前后血清miR-25和miR-101水平变化及临床意义。方法收集来自2017年3月至2018年3月期间在我院择期行胃切除术的82例胃癌患者的术前、术后总共164份血液样本,以及来自健康志愿者的40份样本。运用实时荧光定量聚合酶链反应技术检测标本中miR-25和miR-101的表达水平,并进行统计学分析。结果胃癌组患者术前、术后血清miR-101的相对表达水平均显著性低于健康对照组(P<0.05);而术后血清miR-101的相对表达水平较术前升高,差异具有统计学意义(P<0.05)。胃癌组患者术前、术后血清miR-25的相对表达水平均显著性高于对照组(P<0.05);而术后血清miR-25的相对表达水平较术前降低,差异具有统计学意义(P<0.05)。血清miR-101+miR-25诊断胃癌的AUC为0.913(95%CI:0.843~0.955),灵敏度和特异性分别为76.63%和87.22%。结论胃癌手术前后的血清miR-101、miR-25水平存在明显差异,二者联合诊断胃癌的价值高,单便捷,利于高危人群的大规模筛查以及手术疗效监测。
Objective To investigate the changes and clinical significance of serum miR-25 and miR-101 levels in patients with gastric cancer before and after operation.Methods A total of 164 blood samples from 82 patients with gastric cancer who underwent elective gastrectomy in our hospital from March,2017 to March,2018 were collected,as well as 40 samples from healthy volunteers.The expression levels of miR-25 and miR-101 in these samples were detected by real-time fluorescence quantitative polymerase chain reaction(PCR)and statistical analysis was then performed.Results The relative expression level of serum miR-101 in patients with gastric cancer was significantly lower than those of healthy controls(P<0.05).The relative expression of serum miR-101 after surgery was higher than that of before surgery(P<0.05).The relative expression of serum miR-25 in the gastric cancer group was significantly higher than that of the control group both before and after operation(P<0.05).The relative expression level of serum miR-25 after surgery was lower than that of before surgery(P<0.05).The AUC of serum miR-101 plus miR-25 for the diagnosis of gastric cancer was 0.913(95%CI:0.843-0.955),and the sensitivity and specificity were 76.63%and 87.22%,respectively.Conclusion There are significant differences in serum miR-101 and miR-25 levels before and after gastric cancer surgery.The combination of two markers has a high diagnostic value and convenient usage in gastric cancer,which is conducive for large-scale screening and monitoring of surgical outcomes in high-risk groups.
作者
黄光墉
王金生
HUANG Guang-yong;WANG Jin-sheng(Department of Clinical Laboratory,Guangdong Provincal Shenzhen Municipal Baoan DistrictFuyong Peoplels Hospital,Shenzhen 518103,China)
出处
《标记免疫分析与临床》
CAS
2019年第10期1720-1722,1740,共4页
Labeled Immunoassays and Clinical Medicine
基金
深圳市宝安区科技计划项目(编号:2018JD11)
